Ligand Pharmaceuticals LGND Available-for-Sale Debt Securities - Fair Value by Maturity
Available-for-Sale Debt Securities - Fair Value by Maturity at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's available-for-sale debt securities - fair value by maturity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Ligand Pharmaceuticals's available-for-sale debt securities - fair value by maturity?
- Ligand Pharmaceuticals (LGND) reported available-for-sale debt securities - fair value by maturity of $588.06M in Q1 2026.
- How has Ligand Pharmaceuticals's available-for-sale debt securities - fair value by maturity changed year-over-year?
- Ligand Pharmaceuticals's available-for-sale debt securities - fair value by maturity increased by 353.5% year-over-year, from $129.66M to $588.06M.